1. "Carol Aghajanian"
  2. "2019"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (16)
Groups
  1. Department of Medicine (44)
  2. GDMT, Medicine (44)
  3. Gynecologic Medicine Service (44)
  4. Gynecology Disease Management Team (44)
  5. Solid Tumor Oncology Division (44)
  6. Hematologic Malignancies, Division of (10)

More Groups

People
  1. Carol Aghajanian (44)
  2. Roisin O'Cearbhaill (10)
  3. Karen Cadoo (9)
  4. Vicky Makker (8)
  5. Rachel Grisham (7)
  6. Alexia Iasonos (6)

More People

Years
  1. 2019 (44)
Publications
  1. Journal of Clinical Oncology (14)
  2. Annals of Oncology (7)
  3. Gynecologic Oncology (7)
  4. International Journal of Gynecological Cancer (7)
  5. Lancet Oncology (2)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Elsevier Inc. (8)
  3. Lippincott Williams & Wilkins (7)
  4. Oxford University Press (7)
  5. Elsevier Science, Inc. (3)
  6. American Association for Cancer Research (1)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: Efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the phase III SOLO1 trial
    Meeting Abstract

    Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: An analysis from the phase 3 study ARIEL3
    Meeting Abstract

    Clamp, A. R.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: Post hoc exploratory analyses by BRCA mutation status and patient age
    Meeting Abstract

    Colombo, N.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Meeting Abstract

    Friedlander, M. L.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
    Journal Article

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Ben-Baruch, N. E.; Werner, T. L.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
    Journal Article

    Westin, S. N.; Sill, M. W.; Coleman, R. L.; Waggoner, S.; Moore, K. N.; Mathews, C. A.; Martin, L. P.; Modesitt, S. C.; Lee, S.; Ju, Z.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
    Journal Article

    O'Cearbhaill, R. E.; Deng, W.; Chen, L. M.; Lucci, J. A. 3rd; Behbakht, K.; Spirtos, N. M.; Muller, C. Y.; Benigno, B. B.; Powell, M. A.; Berry, E.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer
    Journal Article

    Cadoo, K. A.; Mandelker, D. L.; Mukherjee, S.; Stewart, C.; DeLair, D.; Ravichandran, V.; Srinivasan, P.; Hurley, D.; Kemel, Y.; Arnold, A. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models
    Journal Article

    Wise, H. C.; Iyer, G. V.; Moore, K.; Temkin, S. M.; Gordon, S.; Aghajanian, C.; Grisham, R. N.
    Scientific Reports (2019)

    Fulltext@MSK | Save